Mirum Pharmaceuticals, Inc. MIRM
89.70
0.34
0.38%
as of 25 Sep
- Market cap
- $5.8B
- P/E
- 0.0×
Follow MIRM
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.87 | 7.61 | 9.54 | 12.00 | |
P/FCF ratio |
192.17 | 132.73 | 0.00 | 0.00 | |
P/Operating CF |
93.55 | 653.56 | (23.77) | (167.66) | |
P/B ratio |
12.71 | 12.60 | 22.42 | 0.00 | |
Price to Tangible BV |
61.72 | 73.74 | 0.00 | 0.00 | |
EV/Sales |
7.73 | 7.47 | 9.41 | 12.51 | |
EV/EBITDA |
0.00 | 1,011.60 | 0.00 | 0.00 | |
EV/Operating CF |
81.58 | 69.71 | (31.35) | (34.02) | |
EV/FCF |
188.74 | 130.27 | (26.47) | (28.24) | |
Quick Ratio |
3.01 | 2.46 | 1.90 | 2.62 | |
Current Ratio |
3.31 | 2.67 | 2.09 | 2.86 | |
Net Debt/EBITDA |
(7.27) | (37.84) | 0.10 | (8.92) | |
Debt/Assets |
39.40% | 36.76% | 34.82% | 71.78% | |
Debt/Equity |
1.06 | 0.98 | 1.28 | (71.97) | |
Asset Turnover |
0.65 | 0.69 | 0.72 | 0.70 | |
Operating CF/Net income |
13.66 | (1.06) | 0.29 | 0.66 | |
Capex/Depreciation |
(0.03) | (0.09) | (1.46) | (3.30) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
32.30% | 34.32% | 515.51% | 60.69% | |
Selling, General and Administrative Expense of Revenue |
46.55% | 49.77% | 60.25% | 46.23% | |
Intangible Assets out of Total Assets |
0.30 | 0.31 | 0.29 | 0.24 | |
Share Based Compensation of Revenue |
13.63% | 12.77% | 22.64% | 17.35% | |
Graham Net Nets |
0.01 | 0.01 | (0.01) | (0.06) | |
Graham Number |
0.00 | 0.00 | 0.00 | 7.33 | |
Earnings Yield |
(1.16%) | (0.60%) | (14.72%) | (12.42%) | |
Free Cash Flow Yield |
0.52% | 0.75% | (3.73%) | (3.69%) | |
Revenue per Share |
2.63 | 2.97 | 2.72 | 2.78 | |
Operating CF per Share |
0.78 | 0.12 | (3.89) | (0.70) | |
Capex per Share |
0.00 | (0.01) | (0.18) | (0.39) | |
Free Cash Flow per Share |
0.78 | 0.11 | (4.07) | (1.09) | |
Cash per Share |
7.42 | 7.64 | 6.56 | 6.92 | |
Shareholders Equity per Share |
5.77 | 6.27 | 4.12 | (0.16) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.77 | 6.27 | 4.12 | (0.16) | |
Free Cash Flow |
39.49 | 5.47 | (239.43) | (69.27) | |
Working Capital |
370.22 | 343.89 | 296.61 | 413.52 | |
Capital Expenditures |
(0.19) | (0.60) | (10.66) | (25.02) | |
Net Current Asset Value |
37.51 | 21.56 | (78.99) | (419.09) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.07 | 0.14 | |
Net Profit Margin |
2.18% | (3.85%) | (494.21%) | (38.14%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
87.83 | 100.81 | 114.48 | 126.10 | |
Average Payables |
10.86 | 12.12 | 35.52 | 20.54 | |
Average Inventory |
22.81 | 23.65 | 23.97 | 24.36 | |
Average Assets |
726.50 | 756.78 | 790.58 | 885.40 | |
Average Common Equity |
262.04 | 270.17 | 237.88 | 122.37 |
Columns are period end dates